Endangering Patient's Access to Care: Proposals to Repeal the Affordable Care Act
Access to lifesaving plasma protein therapies may be endangered by the recent U.S. House of Representatives and U.S. Senate proposals to repeal the Affordable Care Act (ACA).
Patients who rely on these unique medicines also rely on protections included in ACA that:
1. Prohibit lifetime and annual caps on coverage
2. Prohibit being denied coverage because of a pre-existing condition
3. Allow dependent children on their parent’s insurance until age 26
4. Limit maximum out of pocket costs for patients.
Protection for pre-exiting conditions has gained exposure lately, but getting coverage that is permanently lost in a year because of reaching an annual or lifetime cap is an empty promise to patients with rare diseases. “People with hemophilia and other bleeding disorders, alpha-1 antitrypsin deficiency and primary immune deficiency diseases must have access to plasma protein therapies to lead healthy and productive lives,” said PPTA President & CEO, Jan M. Bult. “I feel concerned that patients across the United States with genetic disorders that have nothing to do with lifestyle are faced with the uncertainty of whether or not they will receive their life saving medicine”, continued Bult.
PPTA is working with all of our stakeholders, coalitions and member companies to tell Congress these protections must be preserved in whatever legislative health plan moves forward.